ABSTRACT Hybrid cell lines producing monoclonal antibodies against human prostatic acid phosphatase [PAPase; orthophosphoric-monoester phosphohydrolase (acid optimum), EC 3.1.3.2) were prepared by the fusion ofmouse myeloma cells with the spleen cells of PAPase-immunized BALB/c mice. Approximately 23% of the hybrid cells initially plated after cell fusion produced specific antibodies: 34 microcultures were cloned, and 8 eventually yielded stable cell lines. The monoclonal antibodies produced by these eight hybridomas were characterized for their isotypes, isoelectric points, concentrations, and affinities. All of the eight monoclonal antibodies exhibited strict specificity for PAPase as determined by radioimmunoassay and immunohistochemical methods. These antibodies were used as probes for the antigenic mapping of this enzyme, and three nonoverlapping determinants were recognized. Further binding studies with PAPase fragments, generated by cleavage with a submaxillaris protease, showed that those three determinants are clustered on one fragment of PAPase. These monoclonal antibodies may be useful in refinement of clinical immunoassays of PAPase or immunohistological study of PAPase-synthesizing cells.
Since Gutman et aL reported a correlation between acid phosphatase [orthophosphoric-monoester phosphohydrolase (acid optimum), EC 3.1.3.2] levels in the serum and prostatic cancer over 40 years ago, prostatic acid phosphatase (PAPase) has been regarded as a marker for prostatic adenocarcinoma (1, 2) . Acid phosphatases in serum include lysosomal enzymes of diverse cellular and tissue origins. Diseases other than prostatic cancer are known to cause an elevation of acid phosphatase levels in sera (for review, see refs. 1 and 2). Therefore, antigenic studies of PAPase became important in the development of clinically useful PAPase immunoassays.
Acid phosphatase in humans occurs in a number of different molecular forms: erythrocyte acid phosphatase is distinct from other isoenzymes in its size and kinetic properties (3) . Nearly all differentiated cells synthesize and store acid phosphatase in lysosomes, and this enzyme has been regarded as one of the markers for these organelles (4) . Structural genes for erythrocyte acid phosphatase and for lysosomal isoenzyme have been localized on chromosomes 2 (3) and 11 (5) , respectively.
The human prostate gland secretes PAPase that is a glycoprotein of 100,000 daltons consisting of two identical polypeptide subunits of48,000 daltons (6) . The PAPase is similar to lysosomal acid phosphatase (LAPase) in its molecular size and kinetic properties (2, 7) . However, the two isoenzymes show distinct antigenicities (8) (9) (10) and function. Ultrastructural and cytochemical studies of prostatic epithelial cells revealed that they produce two separate forms ofacid phosphatase, lysosomal and secretory. The secretory acid phosphatase, PAPase, is regulated by androgen and estrogen and is decreased by orchiectomy or hypophysectomy (11) . Although the antigenic and functional differences between the two isoenzymes suggest genetic nonidentity, the chromosomal gene location of PAPase is not yet known.
In the light of these findings, it is important to elucidate the structural and antigenic differences between the two isoenzymes by the use of monoclonal antibodies that recognize different determinants on the PAPase and LAPase molecules. Using the method of Kohler and Milstein (12) , we fused spleen cells from PAPase-immunized mice with mouse myeloma cells and obtained several hybrids producing antibodies reacting specifically with PAPase. This paper describes some properties of these monoclonal antibodies and preliminary antigenic mapping studies with the use of these monoclonal antibodies. A preliminary account of some of this work has appeared (13) .
MATERIALS AND METHODS
Human PAPase and LAPase. Methods of purification and physicochemical and immunochemical evaluations for the purity of PAPase have been described (14, 15) . Details of procedures for the submaxillaris protease digestion of PAPase, tryptic peptide mappings, and affinity labeling of the active site will be described elsewhere. The procedure for LAPase purification has been described (26) .
Cell Cultures. The azaguanine-resistant mouse myeloma cell lines, P3-X63-Ag8 and P3-NS1-Ag4-1 (16), and X63-Ag8.653, a nonsecreting subclone of P3-X63-Ag8 (17) , were grown in Iscove-modified Dulbecco's minimal essential medium (GIBCO) supplied with 10% fetal calfserum and 50 /ig ofgentamycin and 20 Ag of 8-azaguanine per ml (Sigma) (18) . later. A third booster was given in 0.5 ml of saline containing 0.3 ml of pertussis vaccine (a gift of Eli Lilly) 1 month after the second immunization. Three days after the last injection, spleens were removed aseptically, and fusion was performed. The fusion protocol used was essentially that described by Galfr6 et aL (19) . Hybrid cells were selected by hypoxanthine/ aminopterin/thymidine (HAT) medium of Littlefield (20) and maintained according to the feeding schedule described by Galfre et aL (19) . Culture supernates were assayed for antibodies against PAPase by the radioimmunoassay (14) and immunoenzyme assay (15) , and culture medium was changed to HT and then HAT-free Iscove Determination of Affinity Constant. The double antibody radioimmunoassay was used to measure the capacity of antibodies from medium and ascites as described (14, 15 Immunofluorescence. Binding of monoclonal anti-PAPase antibodies to tissue culture cells and histological sections of human tissues was investigated by indirect immunofluorescence as described (15) . The F(ab')2 fragment was prepared from anti-mouse Ig antibodies and labeled with fluorescein by the procedure described by Forni (22) .
Polyacrylamide Gel Electrophoresis. For the identification ofsubunit polypeptides of hybridoma antibodies and ofantigens recognized by monoclonal antibodies, samples were analyzed by sodium dodecyl sulfate/polyacrylamide slab gel electrophoresis and the Tris/glycine buffer system of Laemmli (23) .
Isoelectric Focusing. For the identification of the clonotype pattern ofmonoclonal antibodies, analytical isoelectric focusing of specific antibodies was carried out in a 5% polyacrylamide slab gel (pH gradient, 5.0-9.0; LKB Producer AB, Stockholm, Sweden) as described by the manufacturer. For the bulk purification of monoclonal antibodies, preparative isoelectric focusing was performed in a horizontal layer of Sephadex G-75 with the LKB focusing apparatus as described by Schalch and Braun (24) .
Epitope Saturation Experiment. Monoclonal antibodies harvested from each cell culture flask were first precipitated by (NH4)2SO4 at 50% saturation at 0°C, and antibodies were further purified by immunoadsorbent affinity chromatography. An affinity column matrix was prepared by conjugation of PAPase to CNBr-activated Sepharose 4B (Pharmacia, Uppsala, Sweden). Purified monoclonal antibodies were radioiodinated with " I by the chloramine-T method (25) Table 1 .
Specificity of Monoclonal Antibodies. The specificity of the monoclonal anti-PAPase antibodies described in Table 1 (Table 2) show that the monoclonal antibodies bound exclusively to the Spl fragment. Therefore, it was concluded that all three antigenic determinants recognized by monoclonal antibodies were clustered on the SpI domain. Because the Sp3 fragment was found to regain enzymatic activity after the interaction with heterogeneous rabbit antiPAPase antibodies, it was regarded as the catalytic site (ref. 26; unpublished data). None of these monoclonal antibodies reacted with Sp3.
DISCUSSION
Human PAPase is antigenically different from acid phosphatases ofother tissues. Nevertheless, a small degree of antigenic crossreactivity between PAPase and other lysosomal acid phosphatase(s) has been suspected. In order to resolve this question, we have adopted two approaches-one involving topological mapping through the use of uniquely defined monoclonal antibodies and the second using peptide fragments generated by limited proteolytic digestion.
In order to estimate the number of antigenic determinants on the PAPase, the enzyme was allowed to react with unlabeled monoclonal antibody in antibody excess, and then "MI- were discrepancies of binding ratios among three groups (Fig.  3) . It was reasoned that, if two determinants were overlapping on the PAPase molecule, the corresponding "MI-labeled monoclonal antibodies would show an antigen-to-antibody molar ratio that would be significantly smaller than unity as a result ofsteric hindrance. On the other hand, ifthe two discrete determinants were located at a sufficient distance, their corresponding antibodies would not exhibit any such interference in binding. Because the binding ratios of three groups of monoclonal antibodies to PAPase did not seem to indicate steric hindrance that would result from closely spaced determinants, three nonidentical and nonoverlapping antigenic determinants were ten- During structural studies of prostatic acid phosphatase, we found that limited digestion of the PAPase with submaxillaris protease yielded three antigenically active fragments-Spl, Sp2, and Sp3. The data presented in Table 2 indicate that the three determinants found by these eight monoclonal antibodies are localized only on the Spl fragment. Therefore, the antigenic specificity of PAPase may be attributable to the Spl domain of the molecule.
Previously, we reported the phenomenon of antibody-mediated restoration of catalytic activity for PAPase (10) . We now have confirmed the antibody-mediated restoration of catalytic activity with Sp3 fragments and subunit polypeptides by the use of rabbit anti-PAPase antibodies and rabbit anti-LAPase antibodies. From these observations, we suggest that the Sp3 region of the PAPase molecule contains the enzymatically active site and a "crossreactive" antigenic determinant (26) . With the collective data from structural and antigenic studies, an antigenic map of PAPase has been proposed (Fig. 4) . This map is compatible with the findings that none of the eight monoclonal antibodies was able to restore the catalytic activity of the Sp3 fragment. Monoclonal antibodies described in this paper will be useful for the study of genetic variants of PAPase and the study of tissue distribution of human acid phosphatase. (1982) 
